Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT)

Barclays PLC grew its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 93.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,741 shares of the company's stock after buying an additional 75,064 shares during the quarter. Barclays PLC owned 0.22% of Altimmune worth $956,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Creative Planning raised its holdings in Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company's stock worth $113,000 after acquiring an additional 3,132 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock worth $1,299,000 after purchasing an additional 4,772 shares during the last quarter. Larson Financial Group LLC bought a new stake in shares of Altimmune during the 3rd quarter worth approximately $31,000. Arizona State Retirement System boosted its holdings in shares of Altimmune by 34.4% in the 2nd quarter. Arizona State Retirement System now owns 19,847 shares of the company's stock valued at $132,000 after buying an additional 5,081 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Altimmune by 30.7% in the second quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company's stock valued at $179,000 after buying an additional 6,339 shares in the last quarter. Institutional investors own 78.05% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ALT shares. UBS Group initiated coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Altimmune currently has a consensus rating of "Moderate Buy" and an average target price of $20.00.

Altimmune Stock Performance

Shares of NASDAQ:ALT traded down $0.11 during midday trading on Tuesday, reaching $7.21. The company's stock had a trading volume of 2,646,243 shares, compared to its average volume of 3,795,545. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The firm has a 50 day moving average price of $8.03 and a two-hundred day moving average price of $7.15. The firm has a market capitalization of $512.81 million, a price-to-earnings ratio of -4.65 and a beta of 0.15.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the business posted ($0.39) earnings per share. As a group, research analysts anticipate that Altimmune, Inc. will post -1.36 earnings per share for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.